A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study will be to determine the progression free survival of
patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent
monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two
different regimens of paclitaxel and carboplatin chemotherapy.